Education and training



Download 352.96 Kb.
Page3/3
Date29.01.2017
Size352.96 Kb.
1   2   3
, Johnson, Kimberly F.; Lin, Simon M. (Eds.) 2004.

  • Chen G, Beer DG. Protein Expression Analysis. In CRC Press, “Informatics in Proteomics” Sudhir Sirvastava ed., pp 227-254, 2005.

  • Pass HI, Beer DG, Joseph S, Massion P. Biomarkers and molecular testing for

    early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac

    Surg Clin. 2013 May;23(2):211-24. doi: 10.1016/j.thorsurg.2013.01.002. Epub 2013 Feb 15. PubMed PMID: 23566973.



    Abstracts

    1. Beer DG, Babler M, Papaioannou S, Rapoza N: Plasminogen activator from WI-38 cell cultures. The Pharmacologist 17: 21, 1977.

    2. Yang P, Beer DG, Papaioannou S: The binding of angiotensin II analogs to rat adrenal plasma membrane and glomerulosa cells as compared to the stimulation or inhibition of aldosterone biosynthesis. The Endocrine Society 102:83, 1978.

    3. Hjelle JJ, Grubbs JH, Beer DG, Petersen DR: Inhibition of rat liver aldehyde dehydrogenase by carbontetrachloride. The Toxicologist 2: 135, 1982.

    4. Beer DG: Autoradiographic demonstration of specific binding and nuclear localization of 3H-dexamethasone during normal and neoplastic lung development. Proc Amer Soc Cancer Res. 24: 179, 1983.

    5. Beer DG, Malkinson AM: Autoradiographic localization of 3H- dexamethasone in lung. The Pharmacologist 25: 107, 1983.

    6. Beer DG, Schwarz M, Sawada N, Pitot HC: Oncogene expression in gamma- glutamyl transpeptidase positive hepatocytes isolated during the early stages of hepatocarcinogenesis. Terry Fox Research Conference Proceedings 54, 1985.

    7. Peres G, Maor M, Dann M, Beer DG, Pitot HC, Schwarz M: Detection of albumin, -fetoprotein and actin mRNAs in preneoplastic and neoplastic foci by in situ hybridization. 14th International Cancer Congress, 1986.

    8. Beer DG, Coloma J, Schwarz M, Sawada N, Pitot HC: Protooncogene expression in isolated gamma-glutamyl transpeptidase-positive hepatocytes. Proc Amer Soc Cancer Res. 27: 79, 1986.

    9. Beer DG, Neveu MJ, Paul DL, Pitot HC: Increased expression of the c-raf protooncogene mRNA and decreased expression of the gap junction protein and its mRNA in preneoplastic and neoplastic rat liver lesions. Proc Amer Soc Cancer Res 28: 146, 1987.

    10. Beer DG, Sattler C: Proto-oncogene expression in urethan-induced mouse lung adenomas. Proc Amer Soc Cancer Res 29: 140, 1988.

    11. Nuzum E, Howell A, Droms K, Malkinson A, Beer DG: Structure and expression of the glucocorticoid receptor gene in urethan-induced lung tumors. Proc Amer Soc Cancer Res 30: 308, 1989.

    12. Nuzum EO, Beer DG: Activation and expression of the c-K-ras oncogene in urethan-induced mouse lung tumors and tumor-derived cell lines. The Toxicologist 10: 27, 1990.

    13. Nuzum EO, Malkinson A, Beer DG: Expression of wildtype and activated K- ras alleles in mouse lung tumors. Proc Amer Soc Cancer Res. 31:310, 1990.

    14. Stahl BU, Beer DG, Rozman K: Decreased hepatic phosphoenolpyruvate carboxykinase messenger ribonucleic acid (PEPCK-mRNA) after 2,3,7,8-tetrachlorodibenzo-P-dioxin (TCDD) treatment in the rat. Proc Eurotox Congress p.129, 1991.

    15. Stahl BU, Beer DG, Lebofsky M, Rozman K: Decoupling of phosphoenolypyruvate carboxykinase gene expression from its physiological stimuli after 2,3,7,8-tetrachlorodibenzo-P-dioxin treatment in the male Sprague-Dawley rat. The Toxicologist 12:196, 1992.

    16. Beer DG, Hanson LA, Nuzum EO, Jones BC: K-ras mRNA overexpression in transformed mouse lung cells can cccur by two separate mechanisms. Proc Amer Soc Cancer Res. 33:365, 1992.

    17. Li J, Beer DG: K-ras mRNA regulation in nontransformed mouse lung cells. Proc Amer Soc Cancer Res. 34:519, 1993.

    18. Whyte RI, Bongiorno P, Lesser E, Moore J, Orringer M, Beer DG: Molecular markers of poor prognosis in adenocarcinomas of the lung define unique groups of patients. Amer Assoc Thoracic Surgeons, p132, 1993.

    19. Wu GD, Beer DG, Moore JH, Orringer MB, Appelman HD, Traber PG: Sucrase-isomaltase gene expression in Barrett’s esophagus and adenocarcinoma. Soc Gastroenterology (accepted for Plenary Session presentation), 1993.

    20. Li J, and Beer DG: Transfection of glucocorticoid receptor gene into transformed mouse lung cells containing an activated K-ras allele. Proc Amer Soc Cancer Res. 35:152, 1994.

    21. Xia Lo, Stoll SW, Hardas BD, Liebert M, Grossman HB, Carroll W, Esclamado R, Beer DG, Nelso BR, Johnson TM, Elder JT. Loss of Can19 expression is a common event during epithelial tumor progression in-vivo. J. Invest. Derm. 102 (4): 652-652,1994.

    22. Xia Lo, Liebert M, Grossman HB, Beer DG, Carey TE, Elder JT. Can19 expression is selectively reduced in epithelial tumor-derived cell lines of diverse origin. J. Invest. Derm. 102 (4): 652-652,1994.

    23. Li J, Johnson, TA and Beer DG: Suppression of glucocorticoid-induced growth inhibition by AP-1. Proc Amer Soc Cancer Res. 36:262, 1995.

    24. Beer, DG, Morse MA, Orringer MB. Metabolism and DNA binding of Benzo(a)pyrene in Barrett's metaplasia. Proc Amer Soc Cancer Res. 37:128, 1996.

    25. Thoraval D, Beer D, Asakawa J, Wimmer K, Kuick R, Lamb B, Law D, Hanash S. Genomic alterations in esophageal adenocarcinoma. HUGO Human Genome Meeting, 98, 1996.

    26. Moy J, Orringer MB, Beer DG. Gene amplification in esophageal adenocarcinoma. Proc Amer Soc Cancer Res. 39:132, 1998.

    27. Chang CL, Melhem RF, Beer DG, Kuick R, Hinderer R, Hanash SM. Q18E mutation of Op18 detected in a gastric cardia tumor inhibits cell differentiation. Gastroenterology 114 (4): G2359 Part 2 Suppl. S 1998.

    28. Lin L, Glover TW, Hanash S, Orringer MB, Beer DG. Characterization of an amplicon on 8p22-23 demonstrating regional amplification in esophageal adenocarcinoma. Proc Amer Soc Cancer Res. 40:542, 1999. (AACR-Genetics Institute Young Investigator Award)

    29. Ravikant N, Thoraval D, Zhu Z, Lamb B, Glover TW, Hanash S, Orringer MB, Beer DG. Identification of gene amplification in esophageal adenocarcinoma using 2D genomic scanning. Proc Amer Soc Cancer Res. 40:321, 1999.

    30. Kresty LA, Stoner GD, Normolle D, Beer DG, Appelman H, Eaton T, Fromkes J, Sundaram U, Moselely R, Spechler S, Habib S, Nostrant T, Jewell S. Analysis of Ki-67 and p53 in patients with non-dysplastic intestinal-type Barrett’s esophagus. Proc Amer Soc Cancer Res. 41:223, 2000.

    31. Joe AK, Pinto J, Beer DG, Piazza GA, Thompson WJ, Weinstein IB. Sulidac compounds inhibit growth, induce apoptosis, and enhance glutathione synthesis in Barrett’s-derived cancer cells. Proc Amer Soc Cancer Res. 41:494, 2000.

    32. Lin L, Prescott MS, Orringer MB, Kuick RD, Hanash S, Glover TW, Beer DG. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas using 2D genomic scanning and STS-amplification mapping.Proc Amer Soc Cancer Res. 41:725, 2000.

    33. Aggarwal S, Taneja N, Lin L, Iannettoni MD, Orringer MB, Rehemtulla A, Beer DG. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and activation of caspase 9 independent of Cox-2 expression. Proc Amer Soc Cancer Res. 41:825, 2000.

    34. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells. Proc Amer Soc Cancer Res. 41:812, 2000.

    35. Lord RV, Kawakami K, Brabender J, Danenberg K, Beer DG, Krasna MJ, Tamura G, Fleisher AS, Laird PW, Eads, CA, Danenberg PV, Meltzer SJ. The presence of APC gene hypermethylation in the serum is a specific marker for esophageal adenocarcinoma. Proc Amer Soc Cancer Res. 41:812, 2000.

    36. Joe AK, Liu H, Vural ME, Xiao D, Beer DG, Ting W, Weinstein IB. Resveratrol inhibits growth, induces arrest at the S/G2 transition and apoptosis in several human cancer cell lines. Proc Amer Soc Cancer Res. 42:19, 2001.

    37. Lin L, Prescott MS, Orringer MB, van Dekken H, Misek D, Hanash S , Glover TW, Beer DG. Identification and fine-mapping the core amplified domain of a 3q26 amplicon in primary esophageal and lung cancers. Proc Amer Soc Cancer Res. 42:193, 2001.

    38. Kresty LA, Stoner GD, Normolle D, Beer DG, Appelman H, Eaton T, Rustigi A, Moselely R, Spechler S, Nostrant T, Fromkes J, Sundaram U, Habib S, Jewell S, Hawk E, Brenner D. Analysis of cyclin D1 and EGFR in Barrett’s esophagus patients. Proc Amer Soc Cancer Res. 42:867, 2001.

    39. Arlt MF, Beer DG, Glover TW Multiple fragile sites are deleted in cancer cells.


    Am. J Human Gen 69 (4): 441 Suppl. 1 2001.

    40. Levin AM, Beer DG, Taylor JMG, Kuick R, Giordano TJ, Hanash S, Kardia SLR. Stage III gene expression profiles identify a poor prognosis subgroup of stage I lung adenocarcinomas.Am J Human Gen 69 (4): 476 Suppl. 2001.

    41. Ding I, Liu W, Hu D, Fenton B, Beer D, Okunieff. Celecoxib inhibits radiation induced angiogenic growth factor and cytokine mRNA expression in esophageal carcinoma. Proc Amer Soc Cancer Res. 43:483, 2002.

    42. Brenner D, Normolle D, Kresty LA, Habib S, Beer DG, Eaton T, Rustigi A, Moselely R, Fromkes J, Spechler S, Hawk E, Appelman H, Stoner GD. Effect of difluoromethylornithine (DFMO) upon cellular proliferation and cyclin D expression in human metaplastic Barrett’s esophagus mucosa. Proc Amer Soc Cancer Res. 43:1007, 2002.

    43. Beer D. Developing risk indices for identifying high-risk stage I lung cancer patients. NCI-EORTC, 17-S2, pS19, 2002.

    44. Lin L, Miller CT, Contreras JI, Prescott MS, Yee J, Orringer MB, Misek DE, Hanash SM, Glover TW, Beer DG. The Hepatocyte Nuclear Factor 3 Alpha FOXA1 (HNF3) gene on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Proc Amer Soc Cancer Res. 43:285, 2002.

    45. Chen, G, Gharib TG, Prescott M, Huang CC, Sheddon K,Taylor JMG, Giordano TJ, Thomas DG, Kuick R, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Protein expression profiles predict patient survival in stage I lung adenocarcinoma. Proc Amer Soc Cancer Res. 43:714, 2002.

    46. Brenner D, Normolle D, Kresty LA, Habib S, Beer DG, Eaton T, Wild B, Rustigi A, Moselely R, Fromkes J, Spechler S, Hawk E, Appelman H, Stoner GD. Effect of difluoromethylornithine (DFMO) upon polyamine content in human metaplastic Barrett’s esophagus mucosa. Proc Amer Soc Cancer Res. 43:1146, 2002.

    47. Moore TC, Jepeal LI, Boylan MO, Boyd N, Beer DG, Wolfe MM Functional gastrin receptors are present on adenocarcinoma cells of esophageal origin. Gastroenterology 122 (4): 538 Suppl. 1 2002.

    48. Chen, G, Gharib TG, Thomas DG, Huang CC, Misek DE, Giordano TJ, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Proteomic analysis of Op-18 and elf-5A in lung adenocarcinomas. Proc Amer Soc Cancer Res. 44:322, 2003.

    49. Lin J, Thomas DG, Giordano TJ, Robinson GS, Barve RA, Orringer MB, Beer DG. Melanoma-associated antigens 3 and 10: Potential targets for immunotherapy in Barrett’s adenocarcinoma. Proc Amer Soc Cancer Res. 44:421, 2003.

    50. Lin L Miller CT, Aggarwal S, Lin TK, Contreras JI, Dagenais SL, Orringer MB, Glover TW, Beer DG. Amplification and overexpression of the dual-specificity Yak-related kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Proc Amer Soc Cancer Res. 44:744, 2003.

    51. Lin J, Raoof DA, Thomas DG, Greenson JK, Giordano T, Robinson GS, Barve RA, Orringer MB, Beer DG. L-type amino acid transporter-1 overexpression mediates uptake of melphalan in Barrett's adenocarcinoma J.Am. Col Surg. 197 (3): S10-S11 Suppl., 2003.

    52. Koley H, Shammas M, Munshi N, Beer DG, Goyal R Telomerase as a therapeutic target for Barrett's associated esophageal adenocarcinoma. Gastroenterology 124 (4): A636-A636 Suppl. S 2003.

    53. Lin L, Wang Z, Prescott MS, Albertson DG, van Dekken H, Orringer MB, Glover TW, Thomas DG, Giordano TJ, Beer DG. Regional microsatellite instability precedes allelic amplification in chromosomal band 3q26.3-q27 in the development of Barrett’s adenocarcinomas. Proc. Am Assoc Cancer Res., 2004.

    54. Misek DE, Veenstra C, Hinderer R, Giordano TJ, Beer DG, Hanash SM. Proteomics based idnetification of tumor antigens that induce antibody response in esophageal cancer. Proc. Am Assoc Cancer Res., 2004.

    55. Chen G, Wang H, Miller CT, Thomas DG, Gharig TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM, Beer DG. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. Proc. Am Assoc Cancer Res., 2004.

    56. Raponi M, Yu J, Zhang Y, Chen G, Wang Y, Beer DG. Gene Expression Signatures of Lung Squamous Cell Carcinomas. Proc. Am Assoc Cancer Res., 2005.

    57. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang A, Giordano TJ, Glover TW, Beer DG., Mapping of genomic amplification boundaries of the MET oncogene within fragile site FRA7G and up-regulation of MET signaling pathways in esophageal adenocarcinoma. Proc. Am Assoc Cancer Res., 2005.

    58. Kambhampati S, Ray G, Saxena N, Banerjee S, Sengupta K, Mehta S, Dhar A, Sharma, Van Veldhuizen PJ, Beer DG,. Banerjee SK. Antitumor role of 2-Methoxyestradiol in Barrett's Adenocarcinoma. Proc. Am Assoc Cancer Res., 2005.

    59. Guoan Chen, Xiaoju Wang, Jianjun Yu, Sooryanarayana Varambally, Dafydd G. Thomas, Thomas J. Giordano, Andrew C. Chang, Arul M. Chinnaiyan, David G.Beer Humoral immune response profiles associated with diagnosis and prognosis in lung adenocarcinomas. Proc. Am Assoc Cancer Res., 2005.

    60. Maureen Baird, Samuel K. Kulp, Ching-Shih Chen, David G. Beer Roudabeh J. Jamasbi, Qiang Lu, Laura A. Kresty. A novel histone deacetylase inhibitor, HDAC-42, induces apoptosis, inhibits proliferation and arrests growth of esophageal cancer cells. Proc. Am Assoc Cancer Res., 2005.

    61. Kevin K. Dobbin, David G.Beer, Matthew Meyerson, Timothy J. Yeatman, William L. Gerald, James W. Jacobson, Barbara Conley, Kenneth H. Buetow, Mervi Heiskanen, Richard M. Simon, John D. Minna, Luc Girard, David E. Misek, Jeremy M. G. Taylor, Samir Hanash, Katsuhiko Naoki, D. Neil Hayes, Christine Ladd-Acosta, Steven A. Enkemann, Agnes Viale, Thomas J. Giordano. Inter-laboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Proc. Am Assoc Cancer Res., 2005.

    62. Xiaoying Fu, David G. Beer, Jack Wands, Jose Behar, Weibiao Cao. Role of NADPH oxidase NOX5 in the development of Barrett’s adenocarcinoma cells. Proc. Am Assoc Cancer Res., 2005.

    63. Luc Girard, Chi-Leung Lam, Hisayuki Shigematsu, Maria Pik Wong, Michael Peyton, Shelley Sheridan, David G. Beer, Adi F. Gazdar, John D. Minna. Gene profiling of lung cancers with EGFR mutations. Proc. Am Assoc Cancer Res., 2005.

    64. Xiaoying Fu, David G. Beer, Jack Wands, Jose Behar, Weibiao Cao Cyclic AMP response element binding (CREB) protein is responsible for acid-induced expression of NADPH oxidase NOX5 (short) in Barrett's adenocarcinoma cells.Gastroenterology 128 (4): A131-A132 Suppl. 2, APR 2005.

    65. Younes, M, Rahmani M, Georgakis GG, Beer DG, Younes A. Tamoxifen induces apoptosis in estrogen receptor-beta-positive human esophageal adenocarcinoma cells Gastroenterology 128 (4): A602-A602 Suppl. 2, APR 2005.

    66. Fu X, Beer DG, Wands J, Behar J, Cao W. NADPH oxidase NOX5 contributes to increased proliferation and decreased apoptosis in Barrett's adenocarcinoma cells Gastroenterology. 128 (4): A601-A601 Suppl. 2, APR 2005.

    67. Fu X, Beer D, Wands J, Behar J, Cao W. Role of NADPH oxidase NOX5 in the development of Barrett’s adenocarcinoma. Proc AM Assoc Cancer Res, 2005 46 (4):1127.

    68. Beer DG. Expression profiling of lung cancer and it’s clinical significance. Lung Cancer 49:S14-S15, Suppl. 3, 2005.

    69. Younes, M, Rahmani M, Georgakis GG, Beer DG, Albert VR, Younes A Functional expression of trail receptors trail-R1 and trail-R2 in esophageal adenocarcinoma. Gastroenterology 128 (4): A646-A646 Suppl. 2 APR 2005.

    70. Fu X, Behar J, Eid R, Beer D, Wands J, Cao W. NADPH oxidase NOX5S (short) mediates platelet activating factor (PAF)-induced H2O2 production in Barrett’s adenocarcinoma cells. Gastroenterology 2006:130(4): A566.

    71. Fu X, Behar J, Beer D, Wands J, Lambeth D, Cao W. Rho kinase and ERK2 MAP kinase contribute to acid-induced expression of NAPDH oxidase NOS5S (short) in Barrett’s adenocarcinoma cells. Gastroenterology 2006:130(4): A563.

    72. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, MacDonald J, Thomas D, Moskaluk C, Wang Y, Beer DG. Gene Expression Analyses of Lung Cell for Predicting Prognosis. Int J Molecular Medicine, Vol 18, Suppl. 1, S61, 2006.

    73. Lin L, Lin J, Raoof D, Wang Z, Lin M, Thomas DG, Greenson GK, Giordano TJ, Orringer MB, Chang AC, Beer DG,. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C (UBE2C) in esophageal adenocarcinoma. Proc. Am Assoc Cancer Res., 2007.

    74. Si J, Behar J, Wands J, Fu X, Beer DG, Lambeth D, Chin E, Cao W. STAT5 mediates platelet activating factor (PAF)-induced H2O2 production in Barrett’s adenocarcinoma cells. Gastroenterology 2007.

    75. Si J, Fu X, Behar J, Wands J, Beer DG, Spechler SJ, Souza D, Lambeth D, Cao W. NAPDH oxidase NOS5S mediates acid-induced COX2 expression in production in Barrett’s adenocarcinoma cells. Gastroenterology 2007.

    76. Si J, Behar J, Wands J, Beer DG, Lambeth D, Cao W. Bile acid induced NADPH oxidase NOX5S expression in Barrett’s adenocarcinoma cells. Gastroenterology 2007.

    77. Lam DC, Girard L, Chau WS, et al.Gene expression signatures associated with lung adenocarcinomas in female non-smoker Chinese patients. J. Thor Oncol 2 (8): S378-S378 Suppl. S Aug 2007.

    78. Beer DG. Genomics and proteomics in lung cancer J. Thor Oncol 2 (8): S277-S278 Suppl. S Aug 2007.

    79. Varker KA, Baird ME, Kulp SK, et al. A novel phenylbutyrate-derived histone deacetylase inhibitor, S-HDACi-42, mediates acid-associated gene expression changes in Barrett's esophageal adenocarcinoma cells. Annals of Surg Oncol 14 (2): 77-77 Suppl. S FEB 2007.

    80. Silvers A, Lin L, Wang Z, Chen G, Thomas D, Giordano T, Orringer MB, Beer DG, Chang AC. Selenium Binding Protein 1 expression is decreased during esophageal adenocarcinoma development and potentiates selenium-mediated cisplatinum chemosensitivity in vitro. Proc AM Assoc Cancer Res, 2008.



    81. Lin L, Wang Z, Bass A, Lockwood W, Chang AC, orringer MB, Lam WL, Meyerson M, Beer DG. Identification of a novel amplicon on chromosome 18q11 in esophageal adenocarcinoma. Proc AM Assoc Cancer Res, 2008.

    1. A Qazi, CS Bryant, SKumar, M Prasad, CP Steffes, DG. Beer, RK Goyal, DW Weaver, RB Batchu, and MA Shammas. Sulforaphane, an antioxidant derived from Broccoli, induces apoptotic cell death in Barrett’s esophageal adenocarcinoma cells. Presented at Digestive Disease Week meeting, held in May 2008 in San Diego, CA (Abstract published in April 2008 issue of Gastroenterology).

    2. MA Shammas, A Qazi, RB Batchu, RC Bertheau, JYY Wong, MY Rao, M Prasad, S Ponnazhagan, D Chanda, CP Steffes, NC Munshi, I De Vivo, DG. Beer, S Gryaznov, DW Weaver, & RK Goyal. Impact of Telomerase Inhibition In Barrett’s Esophageal Adenocarcinoma (BEAC). Presented at Digestive Disease Week meeting, held in May 2008 in San Diego, CA (Abstract published in April 2008 issue of Gastroenterology).

    3. KA. Hassan, G Chen, GP Kalemkerian, M Wicha, DG. Beer. An embryonic stem cell-like gene expression signature identifies a poorly differentiated phenotype in lung adenocarcinoma. Proc AM Assoc Cancer Res, 2009.

    4. AL Silvers, L Lin, G Chen, Z Wang, MB Orringer, DG Beer, AC. Chang. Epigenetic and post-transcriptional regulation decreases Selenium Binding Protein 1 (SELENBP1) expression in esophageal adenocarcinoma. Proc AM Assoc Cancer Res, 2009.

    5. P Saintigny, L Zhang, LGirard, Y H. Fan, JJ Lee, RS Herbst, ES Kim, K Coombes, G Blumenschein, A Tsao, DC Lam, WL Gerald, DG Beer, XM Tang, SM Lippman, L Mao, WK Hong, I Wistuba, JD Minna, JV Heymach. Development and testing of a mRNA expression signature correlated with the presence of EGFR mutations in non-small cell lung cancer. IASLC-AACR meeting, Feb 2010.

    6. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer D, Kalemkerian GP, and Wicha M. Notch pathway activity identifies functional lung cancer stem cells and correlates with worse survival in patients with lung adenocarcinoma. American Association for Cancer Research. Abstract #496, Poster presentation, April 2011.

    7. Zhuwen Wang, Dafydd G. Thomas, Mark B. Orringer, David G. Beer, Jules Lin. Significance of Dickkopf-3 overexpression in the pathogenesis of esophageal adenocarcinoma. Proc AACR 52: (#1425), 2011.

    8. Lin L, Bass, AJ, Lockwood, WW, Wang, Z, Silvers AL, Thomas, DG, Chang AC, Lin, J, Orringer, MB, Li, W, Glover, TW, Giordano, TJ, Lam, WL, Meyerson, ML, Beer, DG. Amplification and activation of GATA6 sustain oncogenic lineage-survival in esophageal adenocarcinoma. Proc AACR 53: (#2966), 2012.

    9. S Xi, S Inchauste, Z Xiao, J Shan, M Zhang, JA Hong, MT Raiji, DG Beer, DS Schrump.Epigenetic repression of miR-217 contributes to tobacco-induced esophageal carcinogenesis Proc AACR 54: (#3071), 2013.

    10. Wang Z, L Lin, DG Thomas, MB Orringer, AC Chang, DG Beer, J Lin.Overexpression of CTGF is associated with chemoresistance in esophageal adenocarcinoma. Proc AACR 54: (#3379), 2013.

    11. Wang Z, K Leverenz, DG Thomas, AL Myers, AC Chang, MB Orringer, TJ Giordano, DG Beer,L Lin.Osteopontin (SPP1/OPN) alternative splice variants and metastatic potential in esophageal adenocarcinoma. Proc AACR 54: (#3879), 2013.

    12. Girard L, M Peyton, I Wistuba, Y Xie, R Greer, MB Suraokar, C Behrens, G Xiao, J Heymach, DA Wheeler, CF Davis, K Huffman, D Shames, KR Coombes, AF Gazdar, D CL Lam, DG Beer, JD Minna Molecular signatures of in vitro drug response in lung cancer Proc AACR 54: (# 5589), 2013.

    13. Hirsch FR, Bueno R, Tsao M, Beer D, Harpole D, Mascaux C, Wynes MW, Franklin W, Shepherd F, Gandara D, Govindan R, on behalf of SPECS investigators. 2012. The Squamous Lung Cancer Consortium- The Strategic Partnering to Evaluate Cancer Signatures Program. Oral presentation at the SPORE - Lung Cancer Summer Workshop.

    14. Hirsch FR, Bueno R, Tsao M, Beer D, Harpole D, Wynes MW, Franklin W, Shepherd F, Gandara D, Govindan R, on behalf of SPECS investigators. 2013. The Squamous Lung Cancer Consortium- The Strategic Partnering to Evaluate Cancer Signatures Program. Oral presentation at the 6th International Workshop on Molecular Targeted Therapy in Lung Cancer.

    15. Grabauskiene S, E. Bergeron, MA Morgan, DG Beer, RM Reddy. [C]Chk1 Protein Expression Indicates Sensitivity to Chk1 Inhibition by Antimetabolite Chemotherapy in Non-Small Cell Lung Cancer. Journal of Surgical Research, Volume 179, Issue 2, Pages 313-314, February 2013.

    16. Lin J, Z Wang, DG Thomas, MB Orringer, AC Chang, DG Beer. Inhibition of CTGF Decreases Matrigel Invasion in Esophageal Adenocarcinoma. The Journal of Surgical Research, February 2013 (volume 179 issue 2 Page 186 DOI: 10.1016/j.jss.2012.10.072)



    David G. Beer, Ph.D. 1/29/17




    Download 352.96 Kb.

    Share with your friends:
  • 1   2   3




    The database is protected by copyright ©ininet.org 2020
    send message

        Main page